Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
Published online on November 30, 2022
Abstract
Multiple Sclerosis Journal, Ahead of Print.